The Advisory Board Co. (NASDAQ:ABCO) CFO Michael T. Kirshbaum sold 2,400 shares of The Advisory Board stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $43.01, for a total transaction of $103,224.00. Following the completion of the transaction, the chief financial officer now directly owns 45,503 shares of the company’s stock, valued at approximately $1,957,084.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of The Advisory Board Co. (NASDAQ:ABCO) opened at 43.17 on Wednesday. The firm has a 50-day moving average of $42.49 and a 200 day moving average of $36.21. The company’s market capitalization is $1.74 billion. The Advisory Board Co. has a 12 month low of $18.87 and a 12 month high of $54.84.
The Advisory Board (NASDAQ:ABCO) last announced its earnings results on Wednesday, July 27th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.13. The Advisory Board had a positive return on equity of 11.59% and a negative net margin of 10.21%. The business had revenue of $198.40 million for the quarter, compared to analyst estimates of $196.49 million. During the same quarter last year, the firm earned $0.40 EPS. The Advisory Board’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, equities research analysts expect that The Advisory Board Co. will post $1.86 earnings per share for the current fiscal year.
A number of equities analysts have commented on the stock. William Blair reaffirmed an “outperform” rating on shares of The Advisory Board in a report on Tuesday. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $50.00 price objective on shares of The Advisory Board in a report on Friday, September 16th. Cantor Fitzgerald reissued a “hold” rating on shares of The Advisory Board in a report on Friday, August 19th. Zacks Investment Research raised shares of The Advisory Board from a “hold” rating to a “strong-buy” rating and set a $48.00 price target for the company in a report on Monday, August 1st. Finally, Oppenheimer Holdings Inc. set a $45.00 price target on shares of The Advisory Board and gave the company a “buy” rating in a report on Thursday, July 28th. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The Advisory Board presently has an average rating of “Buy” and an average price target of $43.40.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James & Associates increased its position in The Advisory Board by 0.4% in the second quarter. Raymond James & Associates now owns 7,067 shares of the company’s stock worth $250,000 after buying an additional 28 shares in the last quarter. BlackRock Advisors LLC increased its position in The Advisory Board by 0.4% in the second quarter. BlackRock Advisors LLC now owns 19,655 shares of the company’s stock worth $696,000 after buying an additional 73 shares in the last quarter. Rhumbline Advisers increased its position in The Advisory Board by 0.6% in the second quarter. Rhumbline Advisers now owns 50,804 shares of the company’s stock worth $1,798,000 after buying an additional 292 shares in the last quarter. BlackRock Inc. increased its position in The Advisory Board by 16.2% in the second quarter. BlackRock Inc. now owns 3,263 shares of the company’s stock worth $116,000 after buying an additional 455 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in The Advisory Board by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,856 shares of the company’s stock worth $207,000 after buying an additional 708 shares in the last quarter.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.
Receive News & Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related companies with MarketBeat.com's FREE daily email newsletter.